Naser Kalhor

Naser Kalhor

Auto-generated profile, based on publicly available information

Naser Kalhor

Department of Mesenchymal Stem Cells

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MSMohsen Sheykhhasan
Mohsen Sheykhhasan
NKNaser Kalhor
Naser Kalhor
ASAzar Sheikholeslami
Azar Sheikholeslami
MDMasoumeh Dolati
Masoumeh Dolati
EAElaheh Amini
Elaheh Amini
HFHoda Fazaeli
Hoda Fazaeli
Background. Despite recent advances in scientific knowledge and clinical practice, management, and treatment of breast cancer, as one of the leading causes of female mortality, breast cancer remains a major burden. Recently, methods employing stem cells and their derivatives, i.e., exosomes, in gene‐based therapies hold great promise. Since these natural nanovesicles are able to transmit crucial cellular information which can be engineered to have robust delivery and targeting capacity, they are considered one of the modes of intercellular communication. miR‐145, one of the downregulated microRNAs (miRNAs) in various cancers, can regulate tumor cell invasion, metastasis, apoptosis, and proliferation and stem cell differentiation. Objectives. The aim of this study was to investigate the role of exosomes secreted from adipose tissue‐derived mesenchymal stem cells (MSCs) for miR‐145 transfection into breast cancer cells in order to weaken their expansion and metastasis. Methods. Here, we exploited the exosomes from adipose tissue‐derived mesenchymal stem cells (MSC‐Exo) to deliver miR‐145 in the T‐47D breast cancer cell line. Lentiviral vectors of miR‐145‐pLenti‐III‐enhanced green fluorescent protein (eGFP) and empty pLenti‐III‐eGFP as the backbone were used to transfect MSCs and T‐47D cells. In order to find the efficiency of exosomes as a delivery vehicle, the expression level of some miR‐145 target genes, including Rho‐Associated Coiled‐Coil Containing Protein Kinase 1 (ROCK1), Erb‐B2 Receptor Tyrosine Kinase 2 (ERBB2), Matrix Metalloproteinase 9 (MMP9), and Tumor Protein p53 (TP53), was compared in all treatment groups (T‐47D cells treated by miR‐145‐transfected MSCs and their derivatives or their backbone) and control group (untransfected T‐47D cells) using real‐time PCR. Results. The obtained data represented the inhibitory effect of miR‐145 on apoptosis induction and metastasis in both direct miR‐treated groups. However, exosome‐mediated delivery caused an improved anticancer property of miR‐145. Conclusion. Restoration of miR‐145 using MSC‐Exo can be considered a potential novel therapeutic strategy in breast cancer in the future.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HFHoda Fazaeli
Hoda Fazaeli
NKNaser Kalhor
Naser Kalhor
LNLeila Naserpour
Leila Naserpour
FDFaezeh Davoodi
Faezeh Davoodi
MSMohsen Sheykhhasan
Mohsen Sheykhhasan
ASAzar Sheikholeslami
Azar Sheikholeslami
Background. Exosomes as extracellular vesicles (EVs) are nanoscale intercellular messengers secreted from cells to deliver biological signals. Today, exosomes have become a new field of research in regenerative medicine and are considered as potential therapies to control inflammation and wound healing and enhance and improve healing in many diseases. Given the global burden of osteoarthritis (OA) as the fastest‐growing health condition and one of the major causes of physical disability in the aging population, research to establish EVs as therapeutic products can meet the basic clinical needs in the management of osteoarthritis and provide a therapeutic solution. Objectives. The present study is aimed at evaluating the regenerative potentials of the exosomes secreted from adipose and bone marrow tissue‐derived mesenchymal stem cells (AD‐ and BM‐MSCs) in ameliorating the symptoms of OA. Method. In this experimental study, AD‐ and BM‐MSCs were isolated and cultured in the laboratory until passage 3. Finally, these cells’ secreted exosomes were isolated from their conditioned medium. Ciprofloxacin‐induced OA mouse models underwent intra‐articular injection of exosomes from AD‐MSCs and BM‐MSCs. Finally, the expression levels of collagen I and II, sox9, and aggrecan genes using real‐time PCR, histological analysis, and immunohistochemical (IHC) studies were performed. Results. Real‐time PCR data showed that although the expression level of collagen type II was lower in both exosome‐treated groups than the normal, but it was significantly increased in comparison with the sham and OA, with higher expression in BM‐Exo rather than AD‐Exo group. Similarly, the histological staining and IHC results have provided almost identical data, emphasizing on better therapeutic effect of BM‐MSCs‐exosome than AD‐MSCs‐exosome. Conclusion. BM‐MSCs secreted exosomes in comparison with AD‐MSCs could be considered as a better therapeutic option to improve osteoarthritis and exhibit potential as a disease‐modifying osteoarthritis cell‐free product.

11 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SSSeyedeh Saeideh Sahraei
Seyedeh Saeideh Sahraei
FAFaezeh Davoodi Asl
Faezeh Davoodi Asl
NKNaser Kalhor
Naser Kalhor
MSMohsen Sheykhhasan
Mohsen Sheykhhasan
HFHoda Fazaeli
Hoda Fazaeli
ASAzar Sheikholeslami
Azar Sheikholeslami
Background. Research into the pathogenesis of endometriosis would substantially promote its effective treatment and early diagnosis. Currently, accumulating evidence has shed light on the importance of endometrial stem cells within the menstrual blood which are involved in the establishment and progression of endometriotic lesions in a retrograde manner. Objectives. We aimed to identify the differences in some genes’ expression between menstrual blood‐derived mesenchymal stem cells (MenSCs) isolated from endometriosis patients (E‐MenSCs) and MenSCs from healthy women (NE‐MenSCs). Methods. Menstrual blood samples (2‐3 mL) from healthy and endometriosis women in the age range of 22–35 years were collected. Isolated MenSCs by the Ficoll‐Paque density‐gradient centrifugation method were characterized by flow cytometry. MenSCs were evaluated for key related endometriosis genes by real‐time‐PCR. Results. E‐MenSCs were morphologically different from NE‐MenSCs and showed, respectively, higher and lower expression of CD10 and CD9. Furthermore, E‐MenSCs had higher expression of Cyclin D1 (a cell cycle‐related gene) and MMP‐2 and MMP‐9 (migration‐ and invasion‐related genes) genes compared with NE‐MenSCs. Despite higher cell proliferation in E‐MenSCs, the BAX/BCL‐2 ratio was significantly lower in E‐MenSCs compared to NE‐MenSCs. Also, the level of inflammatory genes such as IL1β, IL6, IL8, and NF‐κB and stemness genes including SOX2 and SALL4 was increased in E‐MenSCs compared with NE‐MenSCs. Further, VEGF, as a potent angiogenic factor, showed a significant increase in E‐MenSCs rather than NE‐MenSCs. However, NE‐MenSCs showed increased ER‐α and β‐catenin when compared with E‐MenSCs. Conclusion. Here, we showed that there are gene expression differences between E‐MenSCs and NE‐MenSCs. These findings propose that MenSCs could play key role in the pathogenesis of endometriosis and further support the menstrual blood retrograde theory of endometriosis formation. This could be of great importance in exploiting promising therapeutic targets and new biomarkers for endometriosis treatment and prognosis.

2 September 2020 in Gerontology
Verified
Journal Article
Closed access
PDF file
HAHossein Afshar
Hossein Afshar
FAFatemeh Adelirad
Fatemeh Adelirad
AKAli Kowsari
Ali Kowsari
NKNaser Kalhor
Naser Kalhor
ADAhmad Delbari
Ahmad Delbari
MOMina Ohadi
Mina Ohadi
Background: Approximately 2% of the human core promoter short tandem repeats (STRs) reach lengths of ≥6 repeats, which may in part be a result of adaptive evolutionary processes and natural selection. A single-exon transcript of the human nescient helix loop helix 2 (NHLH2) gene is flanked by the longest CA-repeat detected in a human protein-coding gene core promoter (Ensembl transcript ID: ENST00000369506.1). NHLH2 is involved in several biological and pathological pathways, such as motivated exercise, obesity, and diabetes. Methods: The allele and genotype distribution of the NHLH2 CA-repeat were investigated by sequencing in 655 Iranian subjects, consisting of late-onset neurocognitive disorder (NCD) as a clinical entity (n = 290) and matched controls (n = 365). The evolutionary trend of the CA-repeat was also studied across vertebrates. Results: The allele range was between 9 and 25 repeats in the NCD cases, and 12 and 24 repeats in the controls. At the frequency of 0.56, the 21-repeat allele was the predominant allele in the controls. While the 21-repeat was also the predominant allele in the NCD patients, we detected significant decline of the frequency (p < 0.0001) and homozygosity (p < 0.006) of this allele in this group. Furthermore, 12 genotypes were detected across 16 patients (5.5% of the entire NCD sample) and not in the controls (disease-only genotypes; p < 0.0003), consisting of at least one extreme allele. The extreme alleles were at 9, 12, 13, 18, and 19 repeats (extreme short end), and 23, 24, and 25 repeats (extreme long end), and their frequencies ranged between 0.001 and 0.04. The frequency of the 21-repeat allele significantly dropped to 0.09 in the disease-only genotype compartment (p < 0.0001). Evolutionarily, while the maximum length of the NHLH2 CA-repeat was 11 repeats in non-primates, this CA-repeat was ≥14 repeats in primates and reached maximum length in human. Conclusion: We propose a novel locus for late-onset NCD at the NHLH2 core promoter exceptionally long CA-STR and natural selection at this locus. Furthermore, there was indication of genotypes at this locus that unambiguously linked to late-onset NCD. This is the first instance of natural selection in favor of a predominantly abundant STR allele in human and its differential distribution in late-onset NCD.

22 December 2022 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
MSMohsen Sheykhhasan
Mohsen Sheykhhasan
HTHamid Tanzadehpanah
Hamid Tanzadehpanah
AAAmirhossein Ahmadieh-Yazdi
Amirhossein Ahmadieh-Yazdi
HMHanie Mahaki
Hanie Mahaki
RSReihaneh Seyedebrahimi
Reihaneh Seyedebrahimi
PDPaola Dama
Paola Dama
(1) Background: Mounting evidence supports the idea that one of the most critical agents in controlling gene expression could be long non-coding RNAs (lncRNAs). Upregulation of lncRNA is observed in the different processes related to pathologies, such as tumor occurrence and development. Among the crescent number of lncRNAs discovered, FLVCR1-AS1 and FBXL19-AS1 have been identified as oncogenes in many cancer progression and prognosis types, including cholangiocarcinoma, gastric cancer, glioma and glioblastoma, hepatocellular carcinoma, lung cancer, ovarian cancer, breast cancer, colorectal cancer, and osteosarcoma. Therefore, abnormal FBXL19-AS1 and FLVCR1-AS1 expression affect a variety of cellular activities, including metastasis, aggressiveness, and proliferation; (2) Methods: This study was searched via PubMed and Google Scholar databases until May 2022; (3) Results: FLVCR1-AS1 and FBXL19-AS1 participate in tumorigenesis and have an active role in impacting several signaling pathways that regulate cell proliferation, migration, invasion, metastasis, and EMT; (4) Conclusions: Our review focuses on the possible molecular mechanisms in a variety of cancers regulated by FLVCR1-AS1 and FBXL19-AS1. It is not surprising that there has been significant interest in the possibility that these lncRNAs might be used as biomarkers for diagnosis or as a target to improve a broader range of cancers in the future.

15 May 2024
Verified
Book Chapter
Open access
PDF file
MSMaryam Sahlolbei
Maryam Sahlolbei
AAAmirhossein Ahmadieh-Yazdi
Amirhossein Ahmadieh-Yazdi
MRMohadeseh Rostamipoor
Mohadeseh Rostamipoor
HMHamed Manoochehri
Hamed Manoochehri
HMHanie Mahaki
Hanie Mahaki
MSMohsen Sheykhhasan
Mohsen Sheykhhasan
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary development in the field of cancer immunotherapy, offering a targeted approach to combat various hematologic malignancies. In this treatment, the patient’s genetically modified T cells are extracted and transformed to produce chimeric antigen receptors (CARs) that are exclusive to cancer cells. These altered T cells identify, attach to, and destroy cancer cells when they are reinfused back into the patient, offering a customized course of therapy. While the CAR T-cell therapy’s clinical success has been most evident in cases of acute lymphoblastic leukemia and certain types of lymphomas, ongoing research aims to extend its applicability to solid tumors. Despite its promise, challenges like cytokine release syndrome and the high cost of treatment remain. Nonetheless, CAR T-cell therapy heralds a new era in cancer treatment, offering a potentially curative approach for patients with otherwise refractory diseases.